Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes

HER2 in Breast Cancer

(2014) Uma Krishnamurti et al.   ADVANCES IN ANATOMIC PATHOLOGY

Current and future role of neoadjuvant therapy for breast cancer

(2014) Michael Untch et al.   BREAST

Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network

(2014) A Borley et al.   BRITISH JOURNAL OF CANCER

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy

(2013) Giuseppe Gullo et al.   BREAST

Breast cancer statistics, 2013

(2013) Carol DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A systematic review of dual targeting in HER2-positive breast cancer

(2013) Iben Kümler et al.   CANCER TREATMENT REVIEWS

High-levelERBB2gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting

(2013) Eva-Maria Fuchs et al.   INTERNATIONAL JOURNAL OF CANCER

Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab

(2013) Carlos Gomez-Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues

(2013) Anna Sapino et al.   Frontiers in Oncology

Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

(2012) Sally Doss et al.   LANCET ONCOLOGY

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

(2012) Hyesil Seol et al.   MODERN PATHOLOGY

Association of HER-2 Copy Number and HER-2/CEP-17 Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast Cancer

(2012) K.-D. Yu et al.   ONCOLOGIST

Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab

(2011) M. Bates et al.   ANNALS OF ONCOLOGY

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

(2011) Angelo Di Leo et al.   LANCET ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

(2010) S Guiu et al.   BRITISH JOURNAL OF CANCER

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab

(2010) Allan Lipton et al.   CANCER

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

(2008) Giuseppe Gullo et al.   INVESTIGATIONAL NEW DRUGS